Sansure Biotech(SH:688289)2025-04-28 16:20Financial Performance - The company's sales reached ¥512,108,285.84, representing a year-on-year increase of 26.60% compared to ¥404,497,043.91 in the same period last year[4]. - Operating revenue for the quarter was ¥475,488,325.65, up 21.62% from ¥390,946,762.39 in the previous year[4]. - Net profit attributable to shareholders was ¥91,735,483.67, reflecting a 13.22% increase from ¥81,024,703.84 year-on-year[4]. - Total revenue for Q1 2025 reached CNY 475,488,325.65, an increase of 21.6% compared to CNY 390,946,762.39 in Q1 2024[17]. - Net profit for Q1 2025 was CNY 80,633,918.47, compared to CNY 73,410,291.06 in Q1 2024, representing a growth of 9.3%[18]. - The net profit attributable to the parent company shareholders for Q1 2025 was approximately ¥91.74 million, an increase from ¥81.02 million in Q1 2024, representing a growth of 13.4%[19]. - The total comprehensive income for Q1 2025 was approximately ¥80.80 million, compared to ¥75.33 million in Q1 2024, reflecting an increase of 7.3%[19]. - The basic and diluted earnings per share for Q1 2025 were both ¥0.16, up from ¥0.14 in Q1 2024, indicating a 14.3% increase[19]. Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥33,816,646.47, a 73.09% reduction compared to a net outflow of ¥125,646,118.28 in the previous year[4][7]. - Cash inflows from operating activities in Q1 2025 totaled approximately ¥384.53 million, down from ¥460.01 million in Q1 2024, a decrease of 16.4%[22]. - The net cash flow from operating activities for Q1 2025 was negative at approximately -¥33.82 million, an improvement from -¥125.65 million in Q1 2024[22]. - Cash outflows from investing activities in Q1 2025 amounted to approximately ¥843.48 million, compared to ¥762.88 million in Q1 2024, an increase of 10.6%[23]. - The net cash flow from investing activities for Q1 2025 was negative at approximately -¥587.50 million, worsening from -¥208.22 million in Q1 2024[23]. - Cash inflows from financing activities in Q1 2025 were approximately ¥823.30 million, significantly higher than ¥426.07 million in Q1 2024, marking an increase of 93.2%[23]. - The net cash flow from financing activities for Q1 2025 was approximately ¥408.14 million, slightly down from ¥421.06 million in Q1 2024[23]. - The ending cash and cash equivalents balance for Q1 2025 was approximately ¥4.26 billion, a slight increase from ¥4.25 billion in Q1 2024[23]. Assets and Liabilities - Total assets increased by 12.56% to ¥9,684,304,892.36 from ¥8,603,796,143.70 at the end of the previous year[5]. - Total assets increased to CNY 9,684,304,892.36 as of March 31, 2025, from CNY 8,603,796,143.70 at the end of 2024[15]. - Total liabilities rose to CNY 2,251,421,445.81 as of March 31, 2025, compared to CNY 1,258,010,592.97 at the end of 2024[15]. - Non-current assets totaled CNY 3,908,114,618.51 as of March 31, 2025, up from CNY 2,814,236,319.40 at the end of 2024[14]. - The company reported a significant increase in fixed assets, which rose to CNY 1,217,392,222.99 from CNY 1,091,496,466.67[14]. - The company’s long-term borrowings increased to CNY 810,162,419.18 as of March 31, 2025, compared to CNY 396,646,274.01 at the end of 2024[15]. - The company’s total equity as of March 31, 2025, was CNY 7,432,883,446.55, slightly up from CNY 7,345,785,550.73 at the end of 2024[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,629[9]. - The largest shareholder, Dai Lizhong, holds 32.83% of the shares, totaling 190,205,090 shares[10]. Research and Development - Research and development expenses totaled ¥61,266,076.45, accounting for 12.88% of operating revenue, down from 16.35% in the previous year[5]. Return on Equity - The weighted average return on equity rose to 1.26%, an increase of 0.14 percentage points from 1.12%[4]. - The company reported non-recurring gains of ¥1,237,647.73 for the period, after accounting for tax effects and minority interests[6].